Trial Profile
A cross sectional study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms X-Sectional
- 13 Jun 2012 Actual patient number is 327 according to ClinicalTrials.gov.
- 12 Oct 2009 New trial record.